Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).

BACKGROUND Little is known about the management of elderly patients with congestive heart failure (CHF) although they represent the majority of the CHF population. Therefore, the TIME-CHF study was set up (1) to evaluate the medical management of very old patients (> or = 75 years) with CHF compared with younger patients (60-74 years), (2) to compare an intensified with a standard treatment approach, and (3) to differentiate between systolic and diastolic dysfunction (ejection fraction < or = 45% vs > 45%). METHODS In a prospective single-blinded multicenter trial, 824 symptomatic patients, CHF hospitalization within the last year and elevated NT-BNP, are randomized to an intensified versus a standard medical therapy. Treatment strategies follow the published guidelines with the aim to reduce symptoms to NYHA class < or = II (standard) or, additionally, NT-BNP levels below twice the upper limit of normal (intensified). The primary end points are 18-month hospitalization-free survival and quality of life. RESULTS By the end of 2004, 297 patients have been included, 147 randomized to intensified and 150 to standard therapy. Mean age in the older age group was 82 +/- 4 years (n = 174) and 69 +/- 4 years in the younger group (n = 123), respectively. Ejection fraction was > 45% in 26% and 10%, respectively. Significant comorbidities were present in 93% of patients. CONCLUSION TIME-CHF will be the first prospective randomized trial to comprehensively study the management of elderly patients with CHF. It will provide unique information comparing two treatment strategies in two age groups irrespective of ejection fraction regarding prognosis, quality of life, as well as resource utilization and costs.

[1]  M. Pahor,et al.  Hypotension and cognitive impairment , 2001, Neurology.

[2]  J. Pell,et al.  Evidence of Improving Prognosis in Heart Failure: Trends in Case Fatality in 66 547 Patients Hospitalized Between 1986 and 1995 , 2000, Circulation.

[3]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[4]  J. Sanderson,et al.  Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. , 2003, The American journal of cardiology.

[5]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[6]  M A Hlatky,et al.  A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). , 1989, The American journal of cardiology.

[7]  H. Ni Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey. , 2003, American heart journal.

[8]  S. Willich,et al.  Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease , 2003, Heart.

[9]  Elizabeth H Bradley,et al.  Understanding the treatment preferences of seriously ill patients. , 2002, The New England journal of medicine.

[10]  Harlan M. Krumholz,et al.  The Burden of Chronic Congestive Heart Failure in Older Persons: Magnitude and Implications for Policy and Research , 2004, Heart Failure Reviews.

[11]  L. Stevenson,et al.  Preferences for quality of life or survival expressed by patients with heart failure. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  K. Bailey,et al.  Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. , 1998, Circulation.

[13]  T. Fukutomi,et al.  Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. , 2004, The American journal of cardiology.

[14]  Harlan M Krumholz,et al.  Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.

[15]  F. Zannad,et al.  Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. , 2004, Journal of the American College of Cardiology.

[16]  J. Cohn,et al.  Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. , 1993, The American journal of cardiology.

[17]  M. Rich,et al.  Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. , 1997, The American journal of cardiology.

[18]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[19]  J. Gottdiener,et al.  Congestive heart failure in the elderly: the Cardiovascular Health Study. , 2004, The American journal of geriatric cardiology.

[20]  A. Abdelhafiz,et al.  Heart failure in older people: causes, diagnosis and treatment. , 2002, Age and ageing.

[21]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[22]  William D. Dupont,et al.  Power and sample size calculations. A review and computer program. , 1990, Controlled clinical trials.

[23]  M. Kodama,et al.  Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. , 2000, Journal of cardiovascular pharmacology.

[24]  H. Krumholz,et al.  Depressive symptoms and risk of functional decline and death in patients with heart failure. , 2001, Journal of the American College of Cardiology.

[25]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[26]  L. Goldman,et al.  Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. , 1998, Circulation.

[27]  H. Krum,et al.  Demographics and concomitant disorders in heart failure , 2003, The Lancet.

[28]  Simon Capewell,et al.  The current cost of heart failure to the National Health Service in the UK , 2002, European journal of heart failure.

[29]  K. Swedberg,et al.  Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. , 2004, European heart journal.

[30]  M. Davies,et al.  Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. , 2002, European heart journal.